Amgen (AMGN) Could Be 29% Overvalued Following Encouraging Phase 3 Trial Data
Amgen (AMGN) Could Be 29% Overvalued Following Encouraging Phase 3 Trial Data Simply Wall St
Covered in this story
Analyst targets on Amgen
- Cantor Fitzgerald: $432 → $440 by Oct 2027 · neutral via MarketBeat
- Wells Fargo: $432 → $430 by Oct 2027 · equal weight via MarketBeat
- Scotiabank: $432 → $500 by Oct 2027 · outperform via MarketBeat
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $AMGN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Amgen →Dalsna Finance is currently tracking 49 stories mentioning Amgen, the earliest published 8 Oct 2026.
Summary aggregated from Simply Wall St's public RSS feed. The full reporting belongs to Simply Wall St — please read it on their site.